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Abstract Congenital disorders of glycosylation (CDG) are
ultra-rare diseases showing a great phenotypic diversity
ranging from mono- to multi-organ/multisystem involve-
ment. Liver involvement, mostly nonprogressive, is often
reported in CDG patients. The main objectives of this work
were (1) to better understand liver involvement in CDG
patients through a liver electronic questionnaire targeting
CDG families (LeQCDG) and (2) to compare responses
from LeQCDG participants with literature review regarding
the prevalence of liver disease and the occurrence of liver
symptoms in CDG patients. The network of patient
advocacy groups, families and professionals (CDG &
Allies – PPAIN) developed the LeQCDG by adapting
validated published questionnaires. The LeQCDG was
approved by an ethics committee, and the recruitment of
patients and caregivers proceeded through social media
platforms. Participants were asked to report past or present
liver-related symptoms (e.g. hepatomegaly, liver fibrosis
and cirrhosis) and laboratory results (e.g. biochemical and/
or radiological). From 11 December 2016 to 22 January
2017, 155 questionnaires were completed. Liver disease
was present in 29.9% of CDG patients. Main symptoms
reported included hepatomegaly, increased levels of serum
transaminases, fibrosis, steatosis and cirrhosis. The data
obtained in this online survey confirm findings from a
recent literature review of 25 years of published evidence
(r ¼ 0.927, P ¼ 0.02). Our questionnaire collected large
amounts of meaningful, clinical and patient-oriented data in
a short period of time without geographic limitations.
Internet-based approaches are especially relevant in the
context of ultra-rare diseases such as CDG.
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QoL Quality of life
Introduction
Congenital Disorders of Glycosylation
Congenital disorders of glycosylation (CDG) are a group of
mostly autosomal recessive disorders first described in
1980 by Jaak Jaeken (Jaeken et al. 1980). It is a rapidly
growing family of very rare genetic diseases comprising
more than 100 different subtypes (Jaeken and Péanne
2017). In glycosylation, glycans (‘sugar trees’) are assem-
bled, processed and attached into proteins or lipids. It is the
most important post-translational modification of proteins
and a fundamental cellular process. Glycosylation defects
are divided in several groups, namely, defects in N- and/or
O-linked glycosylation, in lipid glycosylation and in GPI-
anchor biosynthesis. N-glycosylation defects are the most
common type, with almost 1,000 reported patients with the
most frequent PMM2-CDG.
The majority of CDG patients present multisystem
organ impairment with a vast clinical diversity ranging
from mild to severe dysfunction (Monticelli et al. 2016;
Marques-da-Silva et al. 2017a, b; Francisco et al. 2018).
Liver involvement in CDG also ranges from mild to severe.
Indeed, 22% of patients with CDG subtypes can present
with liver involvement such as elevated serum trans-
aminases, hepatomegaly, steatosis, fibrosis and cirrhosis
(Marques-da-Silva et al. 2017a).
Data on the prevalence, severity and long-term evolution
of liver disease in CDG is sparse. This hampers clinicians
and families in recognizing symptoms and signs and in the
prevention of liver disease-related complications, manage-
ment and treatment. A recent literature review identified
only 99 publications with information relevant to the
subject (Marques-da-Silva et al. 2017a). Consequently,
additional strategies/sources of medical information on this
group of diseases are required.
Nowadays, there is a shift, especially in rare diseases, in
the patient-physician relationship, and patients are often
experts in their own rights obliged to become experts of
their own medical conditions (Budych et al. 2012).
Therefore, gathering data directly from patients and
their caregivers is a unique approach with tremendous
potential.
Quality of Life in Congenital Disorders of Glycosylation
Patient-reported outcomes (PROs) are assessed through
validated questionnaires, which can evaluate quality of life
(QoL) (Erhart et al. 2009; D’Ambrosi et al. 2017; Zeltner
et al. 2016), symptoms (Malcolm et al. 2012; Neijenhuis
et al. 2016), treatment and care satisfaction/effectiveness
(D’Ambrosi et al. 2017) and even compliance to medica-
tion (Geissler et al. 2017). PROs are used clinically, as
secondary endpoints in clinical trials and as tools employed
in natural history studies and patient registries (Coons et al.
2009; Paulsen et al. 2010). Moreover, when patients are
unable to reliably report for themselves, namely, in the case
of children and/or due to the severity of their illness,
impaired language ability speech or cognitive functioning,
PROs may be completed by a proxy such as a parent
(Matza et al. 2013).
Specifically for liver disease, there are already several
validated tools, such as the Hepatitis Quality of Life
Questionnaire (HQLQ), the Chronic Liver Disease
Questionnaire (CLDQ), the Liver Disease Quality of Life
questionnaire (LDQoL), the Liver Disease Symptom Index
2.0 (LDSI 2.0), the post-liver transplant quality of life
(pLTQ) and the polycystic liver disease-specific symptom
questionnaire (PLD-Q), which have been validated in target
populations and have been translated to various languages
(Younossi et al. 2001; Gutteling et al. 2007; Van Der Plas
et al. 2007; Mucci et al. 2010; Saab et al. 2011; Neijenhuis
et al. 2016). Indeed, in a recent study in which both CLDQ
and a general HQoL questionnaire were taken from a
heterogeneous population of patients with chronic liver
disease, it was shown that combining PROs analysis with
clinical objective scores might improve disease diagnosis,
management as well as therapeutic effects (Obradovic et al.
2017).
Performing clinical research in rare diseases, like CDG,
poses many challenges: there is complexity in collecting
robust data in small-sized populations, that are globally
dispersed, which is compounded by lack of funding
(Augustine et al. 2013). Nevertheless, technology offers
innovative approaches that help to overcome these
hurdles. Electronic PROs (ePROs) have been gaining
popularity and, a sudy comparing paper-based and ePROs
revealed that both had the same reliability. The ePROs
also presented advantages over the paper-based PROs,
including the ease of data collection and processing while
being more user-friendly (Coons et al. 2009). Addition-
ally, social media has been emerging as a medical research
recruitment platform, which is particularly helpful for
geographically dispersed populations, like rare disease
communities. Indeed, social media has repeatedly been
used to conduct research surveys and questionnaires with
high adherence and good results (Schumacher et al. 2014;
Davies 2016; Topolovec-Vranic and Natarajan 2016;
Burton-Chase et al. 2017). With 40% of the world
population having access to the Internet, social media-
based medical research is gaining support due to its
accessibility, anonymity, simplicity, affordability, outreach
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and engagement capabilities (Fenner et al. 2012; Davies
2016; Burton-Chase et al. 2017).
Employing social media in clinical research, we imple-
mented an electronic questionnaire aiming to:
1. Better understand liver involvement in CDG patients
through a liver electronic questionnaire targeting
CDG families (LeQCDG) where participants were
asked to report past or present liver-related symptoms
(e.g. hepatomegaly, liver fibrosis and cirrhosis) and
the laboratory findings (e.g. biochemical and/or
radiological).
2. Compare data reported by LeQCDG participants with
previously published literature review regarding the
reported prevalence of liver disease in CDG and the
occurrence of liver symptoms in CDG patients.
The questions implemented in the LeQCDG were based
on a recent literature review focusing on liver involvement
in CDG and inspired us to adapt the existing PROs




To construct the liver electronic questionnaire for CDG
(LeQCDG), we performed a literature search using Google
Scholar and PubMed platforms. The keywords presented in
Table S1 (Supplementary Material) were used to identify
validated tools to evaluate liver-related symptoms and
signs. This search was also performed to find validated
tools to measure quality of life in liver disease patients. To
maximize and refine the number and quality of the retrieved
tools, an additional search was performed as explained in
Table S2 (Supplementary Material). The identified instru-
ments were characterized according to the following
parameters: generic/specific disease questionnaire, main
domains, specific domains, mode of administration, number
of items, score system, completion time, available trans-
lations (cross-cultural studies) and validated tools.
Building and Testing the LeQCDG
Based on the information collected from the above-
mentioned literature search, a liver questionnaire was
constructed. Since we specifically wanted to collect data
from CDG patients, the tool was then tailored to this patient
group. For this, we used information available from our
recent published work (Marques-da-Silva et al. 2017a) that
describes the main liver symptoms reported in CDG
patients. The questionnaire integrated the following sec-
tions: ‘Participants Data’, ‘Liver Signs and Symptoms’,
‘Liver Symptoms’, ‘Impact of Liver Involvement’, ‘Liver
Transplantation’ and ‘Awareness and Information About
Liver Involvement in CDG’.
The online platform used to implement the questionnaire
was SurveyMonkey (http://www.surveymonkey.net –
Copyright#1999–2018 SurveyMonkey) which allowed
construction of the questionnaire with different question
types such as multiple choice, text insertion or classi-
fication scale (Fig. S1 in Supplementary Material). The
SurveyMonkey platform also allows automatic capture of
responses. The questionnaire was an open survey and
directed to CDG patients and caregivers, henceforth
referred to as ‘participants’.
Using the SurveyMonkey platform, the LeQCDG was
pilot tested by relevant partners: two researchers, two
physicians and six CDG caregivers. The pilot testing
included face validity concerning the relevance of the items
as they appear to participants and possible effects of literacy
on reading comprehension. Suggestions derived from the
pilot allowed us to refine the questionnaire to record not
only the views of patients with liver disease but also
patients that had clinical liver-related symptoms, thus
expanding the scope of participants. The sample was
derived from participants reporting on CDG patients with
liver disease, who answered to specific questions regarding
liver symptoms (e.g. incidence of fibrosis, cirrhosis and
portal hypertension).
Questions related to the impact of liver disease on the
wellbeing of the CDG patients were also suggested by our
CDG partners during the piloting phase. A glossary,
explaining different liver disease symptoms, was made
available to participants (Fig. S2 in Supplementary
Material).
LeQCDG Recruitment, Dissemination and Analysis
The LeQCDG was launched online on 11 December 2016
and was available for participation for 42 days, until 22
January 2017. The survey was available in different
languages (English, French, Spanish and Portuguese) and
took between 15 and 20 min to complete. To assure the
participants’ anonymity, the IP identification number of
respondents was not recorded. Multiple entries from the
same individual were avoided choosing the SurveyMonkey
option ‘the questionnaire cannot be answered several times
from the same device’. The respondents could review and
change their answers (in this case, through a ‘Prev.’ button).
The LeQCDG participants were recruited from clinics
and from the CDG community. Due to geographic
limitations, social networks like Facebook, LinkedIn,
Twitter and the Rareconnect platform (https://www.rare-
connect.org/en/community/cdg) were used to disseminate
the LeQCDG to the CDG community. In December 2016 at
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the LeQCDG launching time, the CDG community
included 720 participants of the ‘CDG Global Alliance’, a
closed group on Facebook, and 1,100 followers of the
‘Sindrome CDG’ Facebook page. The Facebook page was
started in 2000, and the members have been responsive to
activity calls. An example of patient engagement in
research activities is the constant participation of the CDG
community in conferences and workshops.
An example of the survey announcement is shown in
Fig. S3 (Supplementary Material). The participants identi-
fied themselves as CDG caregivers or as CDG patients and
as having liver disease or being on a transplant list. Medical
records and disease confirmation were not required for
participation, as we considered ‘random’ participation of
non-CDG patients/caregivers very unlikely.
Epidemiological data suggest that at least 20–30%
of CDG patients may present liver disease symptoms
(Marques-da-Silva et al. 2017a). Therefore, the sample size
should contain, with high probability (e.g. 95%), sufficient
numbers of positive and negative cases of liver disease. To
achieve these conditions and the desired significance level
of P < 0.05, a sample size of minimum 138 participants
was calculated to be necessary, in order to achieve enough
power to allow differentiation of the major liver symptoms
in CDG patients (Lachin 1981).
Data Analysis
LeQCDG responses were exported from SurveyMonkey to
excel. All questionnaires were analysed, except for partic-
ipants reporting unknown CDG types or NGLY1 deficiency
since NGLY-1 is a congenital disorders of deglycosylation
(CDDG) which is different from CDG. These exclusion
criteria were based on the fact that these patients do not
qualify as ‘diagnosed CDG patient’. Descriptive statistics
were used to analyse and report the data. In addition,
correlation between the survey and bibliographic data was
evaluated with Pearson’s linear correlation coefficient and
correspondent P value (Prob>F) using OriginPro 8.5
software (OriginLab Corp., Northampton, USA).
Ethical approval for this study was obtained from the
Ethics Committee at the Faculty of Psychology, Lisbon
University (20/07/2016), and an informed consent was
obtained from all participants. The online survey was
conducted in accordance with the CHERRIES checklist
(Eysenbach 2004).
Results
During 42 days, 203 participants accessed the LeQCDG.
Four participants did not give informed consent and were
excluded from further participation. According to the
CHERRIES checklist (Eysenbach 2004), the completion
rate was 77.9% (a total of 155 out of 199 participants who
agreed to participate).
Participants
All but 1 participant were caregivers (1 was a CDG
patient); 90% (162 out of 180) of participants knew that
CDG patients can be affected by liver disease. Patients of
both sexes were represented in a very similar percentage,
52.8% (95 out of 180) female patients and 47.2% (85 out of
180) male patients (Table S3 in Supplementary Material).
The majority of CDG patients they represented were
10 years or younger (61.2% – 109 out of 178) (Table S4
in Supplementary Material). The major CDG types
represented were PMM2-CDG (76.1% – 137 out of 180)
and ALG6-CDG (4.4% – 8 out of 180) (Fig. S4 in
Supplementary Material). These results were expected since
PMM2-CDG is the most prevalent CDG followed by
ALG6-CDG as the second most prevalent one.
Liver Disease in CDG
Among the CDG patients represented by the participants,
29.9% (53 out of 177) had liver disease, 41.8% (74 out of
177) did not have liver disease, and in 28.3% (50 out of
177) of patients, the participant did not know whether the
CDG patient suffered from liver disease or not. However, in
only 63.6% (105 out of 165) of all CDG patients reported,
biochemical and/or radiological examinations were used to
diagnose liver disease. For 96.1% (49 out of 51) of CDG
patients with liver disease, the diagnosis of liver disease
was made before or at the age of 10 years, and in 49%
(25 out of 51) of the cases, liver problems were diagnosed
before 12 months of age.
Monitoring rate of liver disease is detailed in Table 1.
Hepatomegaly was described in 29% (47 out of 162) of
CDG patients; additional reported symptoms and pathology
Table 1 Monitoring rate of liver function in all CDG patients
Characteristic Value
Monitoring rate of liver function
Twice a year 19.9% (32)
Once a year 37.3% (60)
Once in 2 years 9.9% (16)
Other 30.4% (49)
Don’t know/specify 2.5% (4)
‘Other’ includes every 2 weeks, 6–12 times per year, 3–4 times per
year, once in every 3 years, once and never/no needed. The results are
expressed as percentage and absolute number; the total number of
participants answering this question was 161
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findings were steatosis, ascites, splenomegaly and oeso-
phageal varices (Fig. 1).
Liver Symptoms in CDG
Within the population of CDG patients with known liver
disease (n ¼ 53), 17.6% (9 out of 51) answered that there
was an alternative cause for liver disease put forward
besides CDG; 27.5% (14 out of 51) noticed hepatic
disturbances concomitant with an infectious syndrome.
10.2% (5 out of 49) were taking medication specifically
for their liver condition at the time of the questionnaire.
Liver symptoms were reported as shown in Fig. 2, with a
high incidence of hepatomegaly (61.2% – 30 out of 49) and
increased levels of serum transaminases (51% – 26 out
of 51). Within this group of patients, liver transplantation
was proposed to 5 patients (10.4% – 5 out of 48), 2 of
whom had MPI-CDG and 3 had PMM2-CDG.
In the LeQCDG, 30.2% (39 out of 129) PMM2-CDG
patients reported liver disease, and a specific subgroup
analysis on these patients was performed. The main
symptoms were also hepatomegaly (56.4% – 22 out of
39) and increased levels of serum transaminases (51.3% –
20 out of 39) (Fig. 2). In fact, for PMM2-CDG, we
observed a significant correlation between the results
obtained through the LeQCDG and the descriptions
retrieved from the medical literature (reviewed in Marques-
da-Silva et al. 2017a) (Fig. 3).
Within this subgroup of 39 patients with PMM2-CDG,
liver transplantation was suggested to 3 patients; however
only 1 patient reported severe liver disease in the LeQCDG
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Fig. 2 Prevalence of liver symptoms obtained in the LeQCDG for CDG patients with PMM2-CDG (red) and with other CDG (blue)
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symptoms that include hepatomegaly, increased levels of
transaminases, liver fibrosis, steatosis and cirrhosis. The
other two participants reported only increased levels of
transaminases and in one case also the occurrence of
ascites.
Impact of Liver Involvement
Liver disease-associated symptoms in CDG patients can be
found in Table 2; most symptoms were not present. In line
with this, the participants reported that the liver disease has
no or only minor impact on the patient’s wellbeing and
functioning (Table S5 in Supplementary Material) or
emotional impact (Table S6 in Supplementary Material).
Besides the low impact of liver disease on the physical and
emotional health of CDG patients, most respondents (all
but one being caregivers) reported their constant concerns
regarding physical health and emotional wellbeing of the
patient (Table S7 in Supplementary Material).
Awareness and Information About Liver Involvement in
CDG: All Participants
We found that 50% of the participants that did not know if
the CDG patient they reported on had liver disease also
reported that the possibility of having liver disease has
never been mentioned to the CDG patient. This is at least in
part due to a lack of awareness in the medical community
regarding CDG and related signs and symptoms. The
participants classify the CDG patient’s doctor’s knowledge
about CDG as represented in Table 3. Most participants
think that the medical community should be trained better
about CDG signs and symptoms (42.6% – 66 out of 155)
and/or refer a patient to a more experienced colleague, in
order to help in diagnosis and management (40% – 62 out
of 155).
The treating physicians were reported to have recom-
mended the patient to visit a hepatologist in 23.2% (36 out
of 155) of cases. Approximately 62.6% (97 out of 155) of
the participants feel they should know more about liver
involvement in CDG because this allows them to commu-
nicate and share information with the doctor responsible for
the CDG patient (43.8% – 67 out of 153). The majority of
LeQCDG participants (i.e. 60.6%) gathered information
about liver involvement in CDG themselves. The main
information sources reported were ‘to talk with CDG
treating physician’, ‘information from a patient group
website’ and ‘information from a practical CDG guide’.
However, only 7.7% (12 out of 155) of participants have an
informative document regarding liver disease in CDG.
From all participants, 57.4% (89 out of 155) of the
participants plan to try to learn more about liver involve-
ment in CDG on the next scheduled medical check-up.
Discussion
Principal Results
The results show that 29.9% of the reported CDG patients
have liver disease; in 49% of these patients, the liver
problems were diagnosed before 12 months of age. We
analysed the entire cohort but also analysed the subgroup of





















































Liver clinical symptoms according to LeQCDG (%)
Fig. 3 Scatterplot and regression line (in blue) for the relation
between the prevalence of liver symptoms in PMM2-CDG patients
obtained from LeQCDG results and from literature data (Marques-da-
Silva et al. 2017a). The slope of the regression line was found
1.18  0.24. The 95% confidence interval is plotted as confidence
bands (dashed lines) around the regression line. Pearson’s correlation
coefficient (r) and observed significance of the test (P) are indicated.
The line with slope ¼ 1 corresponds to perfect agreement between
both methods
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PMM2-CDG patients, as this subtype made up 76.1% of
our cohort of participants.
Limitations of This Work
The number of known CDG patients worldwide is
unknown but estimated to be between 1,500 and 2,000.
The number of CDG subtypes that are actually known has
reached a count of 125 and is steadily increasing (Jaeken
and Péanne 2017). These facts make it difficult to estimate
the representative participation of CDG patients overall and
of all CDG subtypes to this questionnaire. One hundred and
fifty-five participants completed the questionnaire, repre-
senting 21 CDG types, and each CDG (apart from PMM2-
CDG) was represented by only a few participants. This
urged us to focus on a sub-analysis of PMM2-CDG, the
CDG with the highest number of participants (76.1%). To
increase the total number of participants and of CDG
subtypes in future work, the recruitment strategy could be
refined, and additional languages could be used.
This is a patient-oriented questionnaire focused on the
patient/caregiver perspective. Due to the lack of a
structured platform to keep files confidentially and in a
secure way, medical records and pathology confirmation
were not reviewed for confirmation of the reported data.
Comparison Between LeQCDG and Literature Data
The major liver disease symptoms identified, within all
CDG or within the subgroup of PMM2-CDG patients, were
hepatomegaly, increased transaminases, liver fibrosis, stea-
tosis and cirrhosis and changes in coagulation factors.
These are the same symptoms as we found in our recent
literature review (Marques-da-Silva et al. 2017a). The good
correlation between both methods (Fig. 3) even for
symptoms with lower prevalence (up to 30% in cirrhosis,
fibrosis and steatosis) indicates that the population sample
in the query was at least as adequate as that in the medical
literature, to allow differentiation of patients with less
common symptoms.
The data from the LeQCDG show prevalence to be
slightly higher to those from the literature review, except
for increased transaminases. This is probably because not
all CDG patients with liver disease are reported, leading to
Table 2 Associated liver symptoms in CDG patients with liver disease
Classification rate 0 1 2 3
Abdominal distension 53% (27) 31% (16) 8% (4) 8% (4)
Feeling sleepy or drowsy during the day (particularly after eating) 55% (28) 24% (12) 14% (7) 8% (4)
Having difficulties sleeping during the night 55% (28) 20% (10) 16% (8) 10% (5)
Nausea 53% (27) 24% (12) 8% (4) 16% (8)
Body temperature fluctuations (too low temperature or fever) 61% (31) 12% (6) 20% (10) 8% (4)
Jaundice (yellow discoloration of the whites of your eyes) 88% (45) 4% (2) 2% (1) 6% (3)
Itching 80% (41) 12% (6) 6% (3) 2% (1)
Bad breath or body odour 69% (35) 20% (10) 4% (2) 8% (4)
Loss of appetite 55% (28) 18% (9) 14% (7) 14% (7)
Pain or discomfort 59% (30) 20% (10) 10% (5) 12% (6)
Fatigue or low levels of energy 31% (16) 33% (17) 16% (8) 20% (10)
The results are expressed as percentage and absolute number; the total number of participants answering this question was 51. Scoring system
used: 0, symptom not present; 1, mild/rare; 2, moderate/sometimes; 3, severe/often
Table 3 Opinion of participants about CDG patient’s doctor’s knowledge about CDG
Question Value






The results are expressed as percentage and absolute number; the total number of participants answering this question was 155
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fewer reports for hepatomegaly, liver fibrosis, steatosis and
cirrhosis in the literature than actually found in the
population. Regarding serum transaminases, the higher
incidence of increased levels obtained in literature may be
due, at least in some cases, to non-hepatic conditions. Liver
transplantation was suggested for PMM2-CDG and MPI-
CDG patients, indicating that liver disease in CDG can
become life-threatening. Inversely, liver disease seems to
have no or minimal impact on the patient’s wellbeing and
functioning in the large majority of patients which can be
related to the low severity of liver disease-associated
symptoms for CDG patients with liver disease described
in this questionnaire. This is in accordance with previous
studies that correlated quality of life and liver disease
severity (Younossi et al. 2001; Saffari et al. 2016;
Neijenhuis et al. 2016). This validates the experience of
LeQCDG participants to evaluate CDG patients’ quality
of life.
The fact that 90% of the LeQCDG participants knew that
CDG may affect the liver and more than half of the
participants will try to learn more about liver disease in
CDG in the next medical check-up of the CDG patient is
important in the context of patient empowerment. In fact, in
an open question requesting additional data from blood
analysis, some participants added quantitative values for
specific parameters, e.g. transaminases. This detailed
information means we can have confidence in the respond-
ents’ knowledge about the CDG patient they are reporting
on.
CDG Electronic Questionnaires as an Additional Source of
Patient Information
The Internet, as a fast source of information and with the
possibility to share health information, represents a potent
tool for collecting data from families of children affected by
rare diseases (Tozzi et al. 2013), such as CDG. Internet-
based electronic questionnaires are increasingly being used
among the rare diseases community to better understand,
for example, the disease impact in terms of health (Molster
et al. 2016; Price et al. 2016) and economy (Chevreul et al.
2016). In this electronic questionnaire, besides the informa-
tion about clinical symptoms related to liver disease and its
impact on the wellbeing of patients, relevant data regarding
CDG awareness and information related to the disease was
also gathered. In doing so, we learned that CDG awareness
and information are lacking within this community mean-
ing that there is a need to educate physicians and create
public awareness on CDG. However, we observed that
regarding clinical information in the LeQCDG, the families
presented additional information that is not described in the
literature. This adds value to available medical CDG
information.
Conclusions
The results obtained with this online questionnaire con-
firmed the data obtained in the previous literature review
(Marques-da-Silva et al. 2017a) in terms of prevalence,
severity and phenotype of liver disease, with a high
incidence of hepatomegaly and increased levels of serum
transaminases. In addition, the consequences of liver
disease on the patient’s wellbeing and the emotional impact
are considered minor, although physical health and emo-
tional wellbeing of the CDG patient are both important
concerns.
The information was collected in 42 days and confirmed
data representing 25 years of scientific publications
dedicated to CDG patients. It should be noted that all the
information was given by the participants that were mostly
family caregivers. This work demonstrated that the partic-
ipants are empowered and capable of completing validated
tools about CDG, clinical symptoms and their impact on the
patient’s quality of life.
We believe that the recent vision on patient-centered
health will move patient associations to embrace patient/
caregiver-driven research within their community. Our
study shows that geographic limitations can be overcome
and that large amounts of meaningful, representative
clinical and patient-oriented data can be collected, in a
short period of time, when patient advocacy groups,
families and professionals (CDG & Allies – PPAIN) work
closely together. These findings and the model of this
questionnaire can be especially relevant for other ultra-rare
diseases.
Note
This study is a result of a collaborative study between
patient advocacy groups, families and professionals
(CDG Professionals and Patient Associations International
Network; CDG & Allies – PPAIN).
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Synopsis
Liver involvement in CDG was accessed through a CDG
family-targeted online questionnaire based on a recent
literature review. Main symptoms reported included hepa-
tomegaly, increased levels of serum transaminases, fibrosis,
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steatosis and cirrhosis. Electronic questionnaires can boost
knowledge on rare diseases, improving possible treatments
and management. This is also useful with regard to future
clinical trials.
Compliance with Ethics Guidelines
Conflict of Interests
Vanessa dos Reis Ferreira is the president and founder of
the Portuguese Association for CDG and other Rare
Metabolic Diseases (APCDG-DMR). All other authors
declare no competing financial interests.
Details of the Contributions of Individual Authors
Dorinda Marques-da-Silva participated in planning, con-
ducted the work, analysed data, conceived the article
outline, participated in the conception and design, drafted
all the manuscript including figures and tables, obtained
final approval of the version to be published and agreed to
be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of
the work were appropriately investigated and resolved.
Rita Francisco participated in conducting the work;
conceiving the article outline, conception and design; and
drafting the manuscript.
Vanessa dos Reis Ferreira participated in planning and
conducting the work; conceiving the article outline,
conception and design; and critically revising it for
important intellectual content.
Liz Forbat participated in conception and design and in
critically revising it for important intellectual content.
Ricardo Lagoa helped in conception and design, data
analysis and drafting the tables and participated in critically
revising the manuscript for important intellectual content.
Paula A. Videira participated in planning the work and
the conception, design and revision of the literature and in
critically revising it for important intellectual content.
Peter Witters participated in conception and design and
in critically revising the manuscript for important intellec-
tual content.
Jaak Jaeken conceived in planning the work and the
article outline; participated in the conception, design and
analysis of the article; and was involved in drafting the
manuscript and critically revising it for important intellec-
tual content.
David Cassiman participated in planning the work and
conceiving the article outline and the conception, design
and analysis of the article and was involved in drafting the
manuscript and in critically revising it for important
intellectual content. He is the guarantor of the article,
accepts full responsibility for the work submitted and
controlled the decision to publish.
All authors gave final approval of the version to be
published.
Ethical Guidelines, Human and Animal Rights and
Consents
This work has been carried out in accordance with The
Code of Ethics of the World Medical Association. Ethical
approval for this study was obtained from the Ethics
Committee at the Faculty of Psychology, Lisbon University
(20/07/2016). Besides, the informed consent was obtained
from participants, and the privacy rights of human subjects
were ensured.
Funding
Dorinda Marques-da-Silva acknowledges the support from
the Rare Disease Foundation’s microgrant and ‘Liliana
Scientific Scholarship’; Rita Francisco acknowledges
Fundação para a Ciência e Tecnologia for the grant
SFRH/BD/124326/2016 awarded to her.
The authors confirmed independence from the sponsors;
the content of the article has not been influenced by
sponsors.
References
Augustine EF, Adams HR, Mink JW (2013) Clinical trials in rare
disease: challenges and opportunities. J Child Neurol
28:1142–1150. https://doi.org/10.1177/0883073813495959
Budych K, Helms TM, Schultz C (2012) How do patients with
rare diseases experience the medical encounter? Exploring
role behavior and its impact on patient-physician interaction.
Health Policy 105:154–164. https://doi.org/10.1016/j.health-
pol.2012.02.018
Burton-Chase AM, Parker WM, Hennig K et al (2017) The use of
social media to recruit participants with rare conditions: lynch
syndrome as an example. JMIR Res Protoc 6:e12. https://doi.org/
10.2196/resprot.6066
Chevreul K, Gandré C, Brigham KB et al (2016) Social/economic
costs and health-related quality of life in patients with fragile X
syndrome in Europe. Eur J Health Econ 17(Suppl 1):43–52.
https://doi.org/10.1007/s10198-016-0784-3
Coons SJ, Gwaltney CJ, Hays RD et al (2009) Recommendations on
evidence needed to support measurement equivalence between
electronic and paper-based patient-reported outcome (PRO)
measures: ISPOR ePRO good research practices task force
report. Value Health 12:419–429
D’Ambrosi R, Ragone V, Caldarini C et al (2017) The impact of
hereditary multiple exostoses on quality of life, satisfaction,
global health status, and pain. Arch Orthop Trauma Surg
137:209–215. https://doi.org/10.1007/s00402-016-2608-4
Davies W (2016) Insights into rare diseases from social media
surveys. Orphanet J Rare Dis 11:1–5. https://doi.org/10.1186/
s13023-016-0532-x
JIMD Reports 63
Erhart M, Ellert U, Kurth BM, Ravens-Sieberer U (2009) Measuring
adolescents’ HRQoL via self reports and parent proxy reports: an
evaluation of the psychometric properties of both versions of the
KINDL-R instrument. Health Qual Life Outcomes 7:77. https://
doi.org/10.1186/1477-7525-7-77
Eysenbach G (2004) Improving the quality of web surveys:
the checklist for reporting results of Internet E-surveys
(CHERRIES). J Med Internet Res 6(3):e34
Fenner Y, Garland SM, Moore EE et al (2012) Web-based recruiting
for health research using a social networking site: an exploratory
study. J Med Internet Res 14:e20. https://doi.org/10.2196/
jmir.1978
Francisco R, Pascoal C, Marques-da-Silva D, Morava E, Gole GA,
Coman DJJ (2018) Keeping an eye on congenital disorders of
O-glycosylation. A systematic literature review. J Inherit Metab
Dis. https://doi.org/10.1007/s10545-017-0119-2
Geissler J, Sharf G, Bombaci F et al (2017) Factors influencing
adherence in CML and ways to improvement: results of a patient-
driven survey of 2546 patients in 63 countries. J Cancer Res Clin
Oncol 143:1167–1176. https://doi.org/10.1007/s00432-017-
2372-z
Gutteling JJ, de Man RA, Busschbach JJ, Darlington AS (2007)
Overview of research on health-related quality of life in patients
with chronic liver disease. Neth J Med 65:227–234
Jaeken J, Péanne R (2017) What is new in CDG? J Inherit Metab Dis
40(4):569–586
Jaeken J, Vanderschueren-Lodeweyckx M, Casaer P et al (1980)
Familial psychomotor retardation with markedly fluctuating
serum prolactin, FSH and GH levels, partial TBG deficiency,
increased serum arylsulfatase A and increased CSF protein: a
new syndrome. Pediatr Res 14:179
Lachin JM (1981) Introduction to sample size determination and
power analysis for clinical trials. Control Clin Trials 2:93–113.
https://doi.org/10.1016/0197-2456(81)90001-5
Malcolm C, Hain R, Gibson F et al (2012) Challenging symptoms in
children with rare life-limiting conditions: findings from a
prospective diary and interview study with families. Acta
Paediatr Int J Paediatr 101:985–992. https://doi.org/10.1111/
j.1651-2227.2012.02680.x
Marques-da-Silva D, dos Reis Ferreira V, Monticelli M et al (2017a)
Liver involvement in congenital disorders of glycosylation
(CDG). A systematic review of the literature. J Inherit Metab
Dis 40:195. https://doi.org/10.1007/s10545-016-0012-4
Marques-da-Silva D, Francisco R, Webster D et al (2017b) Cardiac
complications of congenital disorders of glycosylation (CDG): a
systematic review of the literature. J Inherit Metab Dis 40:657.
https://doi.org/10.1007/s10545-017-0066-y
Matza LS, Patrick DL, Riley AW et al (2013) Pediatric patient-
reported outcome instruments for research to support medical
product labeling: report of the ISPOR PRO good research
practices for the assessment of children and adolescents task
force. Value Health 16:461–479. https://doi.org/10.1016/j.
jval.2013.04.004
Molster C, Urwin D, Di Pietro L et al (2016) Survey of healthcare
experiences of Australian adults living with rare diseases.
Orphanet J Rare Dis 11:30. https://doi.org/10.1186/s13023-016-
0409-z
Monticelli M, Ferro T, Jaeken J et al (2016) Immunological aspects of
congenital disorders of glycosylation (CDG): a review. J Inherit
Metab Dis 39:765–780
Mucci S, Citero VA, Gonzalez AM et al (2010) Cross-cultural
adaptation of the Chronic Liver Disease Questionnaire (CLDQ)
to the Brazilian population. Cad Saude Publica 26:199–205
Neijenhuis MK, Gevers TJG, Hogan MC et al (2016) Development
and validation of a disease-specific questionnaire to assess
patient-reported symptoms in polycystic liver disease. Hepatol-
ogy 64:151–160
Obradovic M, Gluvic Z, Petrovic N et al (2017) A quality of life
assessment and the correlation between generic and disease-
specific questionnaires scores in outpatients with chronic liver
disease-pilot study. Rom J Intern Med 55:129–137. https://doi.
org/10.1515/rjim-2017-0014
Paulsen A, Pedersen AB, Overgaard S, Roos E (2010) Feasibility of
four patient reported outcome measures in the Danish Hip
Arthroplasty Registry. A cross-sectional study of 6000 patients.
Hip Int 20:354
Price MA, Barghout V, Benveniste O et al (2016) Mortality and causes
of death in patients with sporadic inclusion body myositis: survey
study based on the clinical experience of specialists in Australia,
Europe and the USA. J Neuromuscul Dis 3:67–75. https://doi.
org/10.3233/JND-150138
Saab S, Ng V, Landaverde C et al (2011) Development of a disease-
specific questionnaire to measure health-related quality of life in
liver transplant recipients. Liver Transplant 17:567–579
Saffari M, Alavian SM, Naderi MK et al (2016) Cross-cultural
adaptation and psychometric assessment of the liver disease
symptom index 2.0 to measure health-related quality of life
among Iranian patients with chronic hepatitis B. J Transcult Nurs
27:496–508. https://doi.org/10.1177/1043659615577698
Schumacher KR, Stringer KA, Donohue JE et al (2014) Social media
methods for studying rare diseases. Pediatrics 133:e1345–e1353.
https://doi.org/10.1542/peds.2013-2966
Topolovec-Vranic J, Natarajan K (2016) The use of social media in
recruitment for medical research studies: a scoping review. J Med
Internet Res 18:e286
Tozzi AE, Mingarelli R, Agricola E et al (2013) The Internet user
profile of Italian families of patients with rare diseases: a web
survey. Orphanet J Rare Dis 8:76
Van Der Plas SM, Hansen BE, De Boer JB et al (2007) Generic and
disease-specific health related quality of life of liver patients with
various aetiologies: a survey. Qual Life Res 16:375–388. https://
doi.org/10.1007/s11136-006-9131-y
Younossi ZM, Boparai N, Price LL et al (2001) Health-related quality
of life in chronic liver disease: the impact of type and severity of
disease. Am J Gastroenterol 96:2199–2205. https://doi.org/
10.1111/j.1572-0241.2001.03956.x
Zeltner NA et al (2016) Development and validation of a quality of
life questionnaire for paediatric patients with intoxication-type
inborn errors of metabolism. J Inherit Metab Dis 39:S133
64 JIMD Reports
